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The objectives of this study were to determine (i) whether an association exists
between individual pharmacokinetic parameters and treatment outcome when
feeder cattle were diagnosed with bovine respiratory disease (BRD) and treated
with gamithromycin (Zactranâ) at the label dose and (ii) whether there was a
stronger association between treatment outcome and gamithromycin concentration in plasma or in the pulmonary epithelial lining fluid (PELF) effect compartment. The study design was a prospective, blinded, randomized clinical trial
utilizing three groups of 60 (362–592 lb) steers/bulls randomly allocated
within origin to sham injection or gamithromycin mass medication. Cattle were
evaluated daily for signs of BRD by a veterinarian blinded to treatment. Animals meeting the BRD case definition were enrolled and allocated to a sample
collection scheme consisting of samples for bacterial isolation (bronchoalveolar
lavage fluid and nasopharyngeal swabs) and gamithromycin concentration
determination (PELF and plasma). Gamithromycin susceptibility of
M. haemolytica (n = 287) and P. multocida (n = 257) were determined using
broth microdilution with frozen panels containing gamithromycin at concentrations from 0.03 to 16 lg/mL. A two-compartment plasma pharmacokinetic
model with an additional compartment for gamithromycin in PELF was developed using rich data sets from published and unpublished studies. The sparse
data from our study were then fit to this model using nonlinear mixed effects
modeling to estimate individual parameter values. The resulting parameter estimates were used to simulate full time–concentration profiles for each animal in
this study. These profiles were analyzed using noncompartmental methods so
that PK/PD indices (AUC24/MIC, AUC∞/MIC, CMAX/MIC) could be calculated
for plasma and PELF (also T>MIC) for each individual. The calculated PK/PD
indices were indicative that for both M. haemolytica and P. multocida a higher
drug exposure in terms of concentration, and duration of exposure relative to
the MIC of the target pathogen, was favorable to a successful case outcome.
A significant association was found between treatment success and PELF
AUC0–24/MIC for P. multocida. The calves in this study demonstrated an
increased clearance and volume of distribution in plasma as compared to the
healthy calves in two previously published reports. Ultimately, the findings
from this study indicate that higher PK/PD indices were predictive of positive
treatment outcomes.
(Paper received 2 February 2015; accepted for publication 3 August 2015)
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INTRODUCTION
Gamithromycin (ZACTRANâ; Merial Animal Health, Duluth,
GA, USA), a macrolide of the azalide subclass, is approved for
both treatment of BRD caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis and
the control of BRD caused by M. haemolytica and P. multocida
(Food and Drug Administration (FDA), 2011). Macrolide
antibiotics, in general, are bacteriostatic through the inhibition
of bacterial RNA-dependent protein biosynthesis (Jain & Danziger, 2004). However, gamithromycin can also be bactericidal
with minimum bactericidal concentrations only 1 dilution
higher than the respective MIC (Huang et al., 2010). The tendency for macrolides, especially azalides, to accumulate in
inflamed tissue has been described previously (Amsden, 2001).
This fact coupled with the known extensive tissue distribution
of macrolides has sparked interest in the veterinary literature
concerning the exposure–response relationship at the site of
action as it pertains to the newer long-acting injectable macrolide formulations (Nowakowski et al., 2004; Womble et al.,
2006; Venner et al., 2010; Menge et al., 2012; Villarino et al.,
2013a,b, 2014).
Recent work examining the concentrations of antibiotics in
PELF of healthy animals has been performed to describe the
disposition of gamithromycin in beef calves (Giguere et al.,
2011). Giguere et al. found that gamithromycin was rapidly
absorbed and reached potentially therapeutic concentrations in
PELF within 30 min after s.c. administration. To the authors’
knowledge, all previous work describing the distribution of
these drugs in cattle has been performed in healthy subjects
and there are no publications describing the PK and PD of a
macrolide class antibiotic in the PELF under the conditions of
naturally occurring BRD. To that end, the objectives of this
study were to (i) develop a compartmental PK model based
upon existing PK data, (ii) use sparse data collected in this
study to estimate parameter values for the animals in this
study population, (iii) use the model estimated parameters to
simulate complete concentration–time profiles of gamithromycin in the central and PELF effect compartments of each animal, (iv) determine if a relationship exists between plasma
and/or PELF concentrations and treatment outcome, and
finally (v) determine the PK/PD indices associated with treatment success in naturally occurring BRD.

they were housed in open air, dirt floor group housing pens for
the duration of the trial.
Study design and treatment allocation
The study design was a prospective, blinded, randomized clinical trial with masked subjective evaluators and was approved
by the Kansas State University Institutional Animal Care and
Use Committee.
Cattle were randomized to one of two treatments prior to
arrival (by ear tag ID administered at the sale barn) so that
each load was randomly allocated into two pens per source,
one for each treatment (6 total pens in the study, 3 for each
treatment). At initial processing, cattle assigned to treatment 1
served as untreated controls (CON) receiving saline at 2 mL/
110 pounds subcutaneously in the neck, while cattle randomly
allocated to treatment 2 received treatment (MM) for the control of BRD with gamithromycin at the label dose of 6 mg/kg
(2 mL/110 lb) subcutaneously in the neck. Additionally, all
cattle received a modified live viral respiratory vaccine, clostridia vaccine, growth implant, injectable anthelminthic, and
duplicate tags for study identification and were examined to
ensure that no clinical signs of BRD were present on arrival.
Once in their pens, cattle were fed a ration according to practices typical of the feedlot industry.
Clinical scoring and disease diagnosis
Daily pen observations were performed by a veterinarian
masked to treatment allocation. Clinical scoring was by exclusion, that is, only cattle scoring 1–4, as described in Table 1,
were recorded on daily observation forms and brought to the
chute for further evaluation. Cattle having a rectal temperature
of ≥104.0°F (≥40.0 °C) and a clinical score of ≥1 were diagnosed with BRD and included in this study. Cattle with a clinical score of ≥1 but not meeting the temperature requirements
were returned to their home pen without treatment for further
observation. Animals were clinically scored each day but were
not eligible for treatment of BRD until the postcontrol
Table 1. Description of clinical scoring criteria used for daily clinical
observations of feeder cattle to assist in diagnosis of bovine respiratory
disease. Clinical scoring was performed by a veterinarian masked to
study treatment allocation
Score

MATERIALS AND METHODS
Animals and husbandry
One hundred and eighty cattle judged to be at high risk for
BRD [overall average body weight of 470 pounds (362–
592 lbs)] were sourced from Athens, Tennessee (n = 60), Richmond, Kentucky (n = 60), and Maryville, Missouri (n = 60), as
part of another study. Commingled steers and bulls of multiple
origins and mixed breeds were acquired at each sale barn and
transported to a small research feeding facility in Kansas where

0
1

2

3
4

Description
No abnormal signs
Slower than pen mates but still perks up when approached;
does not appear weak; actively follows movements with
raised head
Stands with head lowered; perks up when approached but
returns to depressed stance; moves slowly and falls to
back of group; may display signs of weakness such as
incoordination
Obviously very weak; difficulty in moving with group;
raises head only when approached closely
Moribund, unable to rise
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treatment moratorium had elapsed. Control animals were
immediately eligible for treatment of BRD, and those receiving
mass medication were eligible for treatment on study day 8 (7
day moratorium).
Sampling allocation and collection procedures
The day of enrollment (first diagnosis of BRD) was designated
as Day 0 for each calf. Cattle meeting inclusion criteria for the
study were randomly allocated to a sample collection scheme
consisting of a collection of NPS, BAL, and plasma (Table 2).
Allocation to sample collection procedures was performed in
advance, in blocks of three, to ensure that there was an equal
distribution across sampling time points in order to account for
the fact that actual number of cases of naturally occurring
BRD was unknown beforehand. Samples collected on Day 0
were collected just prior to treatment with gamithromycin. All
treatments and procedures at the chute were performed by
trained personnel not involved in clinical scoring of cattle. The
veterinarian responsible for clinical scoring was not present for
treatments and procedures performed at the chute and therefore remained masked throughout the duration of the study
period. Deep nasopharyngeal swabs and an aliquot of BAL fluid
were immediately sent for bacterial culture, while samples of
plasma and BAL fluid were processed and frozen at <70 °C
for later analysis by HPLC-MS/MS.
The BAL procedure was used to collect PELF fluid from manually restrained, nonsedate cattle. The BAL tube (Bivonna, BAL240) was introduced into the trachea via the nasal passage and
advanced until wedged into a deep bronchus. Sterile saline
(240 mL) was infused in 60 mL aliquots and aspirated immediately after each aliquot. Recovered BAL fluid was collected into a
250 mL centrifuge tube, mixed well, divided evenly among four
50-mL centrifuge tubes, and then placed on ice and centrifuged
in the feedlot laboratory within 40 min of collection. One randomly selected cell pellet was resuspended in liquid Amies media
and submitted to the KSVDL for bacterial isolation. The BAL
tubes were cleaned by plasma sterilization between collection
procedures to prevent cross-contamination.
Deep nasopharyngeal swabs were collected from both nares
by a veterinarian trained in the procedure. Briefly, a double
guarded sterile uterine swab was introduced through the nares
Table 2. Sampling scheme for bronchoalveolar lavage (BAL), deep
nasopharyngeal swabs (NPS), and plasma in cattle diagnosed with
bovine respiratory disease (BRD). The top row is hours after treatment,
and 0 h is just prior to treatment with gamithromycin. The number
of cattle enrolled in each collection scheme is represented in the first
column (labeled N)
N

0h

8
9

BAL/Plasma/
NPS
Plasma/NPS

9

Plasma/NPS

12 h

24 h

120 h

Plasma

Plasma

BAL/Plasma/NPS

BAL/Plasma/
NPS
Plasma

Plasma

BAL/Plasma/NPS

BAL/Plasma/
NPS

BAL/Plasma/NPS
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into the nasal cavity and guided to the point where resistance
was met in the area of the nasopharyngeal tonsilar tissue. At
this point, the double guarded swab was retracted slightly, the
interior sleeve portion containing the swab was pushed
through the exterior guard, and the swab advanced from the
sleeve and rotated to ensure a sufficient sample of the mucous
and tonsilar secretions from the pharyngeal tissues. The swab
was retracted into the guarded sleeve to prevent contamination
while exiting the nares. The swabs were placed in liquid Amies
media and transported on ice to the KSVDL for bacterial culture and isolation.
Blood was collected into 10-mL sodium heparin vacutainer
tubes via jugular venipuncture, and tubes were centrifuged in
the feedlot laboratory at 500 g for 15 min. Plasma was pipetted into duplicate cryovials and stored along with other cryovial samples of BAL fluid (duplicates of PELF fluid,
resuspended cell pellets, and urea analysis samples from both
PELF and plasma) at <70 °C until analysis.
Treatment administration and case outcome determination
Cattle diagnosed with BRD were randomly assigned to a sample collection scheme, treated with gamithromycin according
to label directions (6 mg/kg) s.c. in the neck, and returned to
the home pen. Case outcome was determined until Day 9,
post-treatment. A treatment failure was defined as the calf
meeting study inclusion criteria as previously described, if the
calf was recorded a clinical score 3 regardless of rectal temperature, or if a calf died from BRD. Those cattle not categorized
as a treatment failure by Day 9 were therefore considered
treatment successes. Therefore, comparisons within this manuscript are between cattle that were deemed a treatment success
versus those that were deemed a treatment failure.
Gamithromycin concentration analysis
Concentrations of gamithromycin in PELF and plasma were
determined by Merial personnel masked to treatment. Samples
were analyzed by reversed-phase HPLC with detection via MS/
MS transitions by methods previously described (Giguere et al.,
2011). The limit of detection and limit of quantitation were 5
and 10 ng/mL, respectively. The concentration of gamithromycin in PELF was estimated using the ratio of urea in BAL fluid
to that as measured in serum as described previously (Rennard
et al., 1986).
Bacterial isolation and MIC determination
Nasopharyngeal swabs and PELF samples were plated directly
onto trypticase soy + 5% blood, chocolate, and MacConkey
agar plates and incubated in 5% CO2 at 37 °C for 18–24 h.
Up to 12 colonies displaying growth characteristics typical of
M. haemolytica and P. multocida were isolated in pure culture.
Identity was confirmed using MALDI-TOFâ (Bruker Daltonics,
Billerica, MA, USA) and frozen for later susceptibility testing at
the USMARC in Clay Center, Nebraska.
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Gamithromycin susceptibility of M. haemolytica and P. multocida isolates was performed at USMARC by broth microdilution
with frozen panels from TREK Diagnostic Systemsâ (ThermoFisher Scientific Inc., Waltham, MA, USA) containing gamithromycin at concentrations ranging from 0.03 to 16 lg/mL. Bacterial suspensions were prepared and susceptibility plates
inoculated as per CLSI guidelines (Clinical and Laboratory Standards Institute VET01-A4, 2013). In brief, isolates were cultured
on chocolate agar and incubated with increased CO2 at 37 °C
for 18–20 h. Bacterial suspensions equivalent to 0.5 McFarland
standard were made by suspending 3 to 5 isolated colonies from
each plate, into 5 mL of demineralized water. Mueller–Hinton
broth tubes were then inoculated with 140 lL of the resulting
bacterial suspensions. A 12-channel pipette was used to dispense
50 lL of this suspension into each of 12 wells in the panel, such
that each panel could be used to evaluate the susceptibility of 8
strains. Plates were sealed and incubated at 37 °C for 18–20 h
at which time the plates were visually inspected and MIC values
determined by noting the lowest concentration of antibiotic that
completely inhibited growth. Determination of susceptible, intermediate, or resistant was based off of clinical breakpoints established for gamithromycin by CLSI (Clinical and Laboratory
Standards Institute VET01-A4, 2013).
Pharmacokinetic modeling and pharmacodynamics
A user-defined, two compartment plus PELF compartment was
built in Phoenix NLMEâ (Certara L.P., Cary, NC, USA). The
model schematic can be seen in Fig. 1. The differential equation describing this model is as follows:
dA1
¼ ðA1  k10 Þ þ ðAa  Ka Þ  ðA1  k12  A2  k21 Þ
dt
 ðA1  k13  Apelf  k31 Þ
dA2
¼ ðA1  k12  A2  k21 Þ
dt
dApelf
¼ ðA1  k13  Apelf  k31 Þ
dt
where A1 is the amount in central compartment, k10 is the
elimination rate constant from the central compartment, Aa

is the amount at the site of the s.c. injection, Ka is the
absorption rate constant from the site of the injection, k12 is
the rate constant for the central to the peripheral compartment, A2 is the amount in the peripheral compartment, k21
is the rate constant for the peripheral to the central compartment, k13 is the rate constant for the central to the
PELF compartment, Apelf is the amount in the PELF compartment, and k31 is the rate constant for the PELF to the central compartment.
Data collected from published (Huang et al., 2010; Giguere
et al., 2011) and unpublished (personal communication with
coauthor RKT) PK trials of gamithromycin in cattle were used
to generate initial estimates to develop the model. These data
consisted of samples of plasma and PELF concentrations after
administration of the label dosage of gamithromycin in healthy
beef calves. When specific data were not available in the
manuscript, data were extracted using an online tool,
WebPlotDigitizer (http://arohatgi.info/WebPlotDigitizer/).
Next, the sparse data from this trial were integrated into the
model using a nonlinear mixed effects approach, without the
inclusion of covariates, to predict parameter values for each
animal in our study. Parameter values were calculated for
each individual animal within this study by use of the typical
value and the individual ETA [e.g., V = tvV*exp(nV)]. Individual ETA values for each parameter of the PK model can be
found online in supplemental materials. One hundred simulations were conducted, predicting complete plasma and PELF
time–concentration curves for each animal in this study. Average simulated data were analyzed by NCA in order to compare
the results of this study to those in the literature and to calculate PK/PD indices for plasma (AUC24/MIC, AUC∞/MIC, CMAX/
MIC) and PELF (AUC24/MIC, AUC∞/MIC, CMAX/MIC, T>MIC).
Clearance and V were calculated from extrapolated graphical
data contained in each manuscript as follows and for the
calves in this study: Cl = Dose/AUCinf and V = Cl/Kel.
The PK/PD indices were calculated from AUC24, AUC∞, and
CMAX of the simulated plasma and PELF time–concentration
profiles of each individual animal and the MIC of the sample
collected from that animal. T>MIC was calculated using predicted PELF data only because plasma concentrations did not
reach levels above the MICs in this study. The MIC used for
the calculation was from the isolate with the highest MIC collected from that calf at time 0 only (i.e., prior to therapeutic
treatment) but could be from either BAL or NPS. Time above
MIC was not calculated for plasma as the plasma concentrations did not reach that of the lowest MIC dilution tested.
Statistical analysis

Fig. 1. Schematic representation of the final pharmacokinetic model for the
two compartment plus PELF effect compartment for concentration of gamithromycin in feedlot cattle diagnosed with bovine respiratory disease.

A generalized linear mixed model fit by maximum-likelihood
regression was built in STATA (Stata/SE 12.1 for Windows;
StataCorp LP, College Station, TX, USA) to compare morbidity
between MM and CON using pen as a random clustering effect.
Initial covariates included in the model, but ultimately
excluded due to lack of significance, were trailer compartment
and state of animal origination.
© 2015 John Wiley & Sons Ltd
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Table 3. Summary comparison of morbidity, mortality, and treatment
failure rates of bovine respiratory disease among feedlot cattle allocated
to either sham injection or mass medication with gamithromycin at
6 mg/kg. Treatment for BRD was also with gamithromycin at the time
of BRD diagnosis by a veterinarian

Statistical comparisons of PK and PD parameters between
treatment outcome (success and failure) were performed with
the Kruskal–Wallis test for nonparametric data using SASâ
software (Version 9.3; SAS Institute Inc., Cary, NC, USA). The
level of significance was set at P ≤ 0.05 using a two-tailed test.
Both compartmental and NCA PK parameters were compared
statistically as this report focuses on both types of modeling.

Morbidity from BRD
Mortality from BRD
BRD treatment
failure

RESULTS
Morbidity outcome

Control (%)

Mass medicated
(%)

Total (%)

17/90 (18.9)
0
2/17 (11.8)

9/90 (10.0)
0
2/9 (22.2)

26/180 (14.4)
0
4/26 (15.4)

The numerical differences were not statistically significant (% = percentage of subjects).

Descriptive morbidity, mortality, and treatment failure data
can be found in Table 3. Treatment for control of BRD with
gamithromycin resulted in a numerically lower morbidity but
a numerically higher relapse rate (therapeutic failure); however, these differences were not statistically significant
(P = 0.25). Total morbidity throughout the 28 days of the trial
was much lower than anticipated, and the power of the study
may therefore have been insufficient to detect significant differences in morbidity between sham-injected cattle and those
treated for control of BRD with gamithromycin.

seen in Fig. 2. There is an excellent fit of predicted data to
actual data in plasma and PELF at lower concentrations. The
model slightly under-predicts PELF at higher concentrations,
but this is likely due to difficulty in accurately predicting the
Ka due to the paucity of data in this area of the curve.
Pharmacokinetics of study animals
The estimated typical value of the compartmental model
parameters for the population (regardless of treatment outcome) are summarized in Table 4. Note that the volume
parameters (V and VPELF) are not weight normalized because

PK model development
Model development was guided by goodness-of-fit plots within
the modeling software. The results of the final model can be

Plasma

500
450

Observed (ng/mL)

400
350
300
250
200
150
100
50
0

0

50

100

150

200

250

300

350

400

450

Individual predicted (ng/mL)
PELF

12000

Fig. 2. Goodness-of-fit plots for model predicted
data versus actual observed data from two
previously published studies (Huang et al.,
2010; Giguere et al., 2011) and data obtained
from personal communication with one of the
co-authors (RKT).
© 2015 John Wiley & Sons Ltd
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Plasma concentration (µg/mL)

V
k10
Ka
k12
k21
k13
k31
VPELF

Units

Estimates

L
1/h
1/h
1/h
1/h
1/h
1/h
L

183
1.84
8.83
7.09
0.26
0.98
0.02
201

0.14

176

174

180
160

M. haemolyca

140

P. multocida

120

97

100
80
53

60
40

26

20
0

3

1
≤0.03

0.06

0.12

0.25

0.5

1

12

1
2

4

1
8

≥16

Minimum inhibitory concentraon (μg/mL)

Fig. 4. Frequency distribution of clinical isolates of Mannheimia
haemolytica (n = 287) and Pasteurella multocida (n = 257) MIC to gamithromycin cultured from bronchoalveolar and nasopharyngeal samples
from cattle diagnosed with bovine respiratory disease. Samples were
collected at time 0, 12, 24, and 120 h post-treatment. Numbers above
bars represent isolate number at that respective MIC dilution.

0.12
Treatment
success

0.1
0.08

Treatment
failure

0.06
0.04
0.02
0

0

24

48

72

96

120 144
Time (h)

168

192

216

240

4
PELF concentration (µg/mL)

200

Number of isolates

Table 4. Population pharmacokinetic parameter estimates following
administration of gamithromycin administered at an average dose of
6 mg/kg subcutaneously for the treatment of acute bovine respiratory
disease

3.5
3
Treatment
success

2.5
2

Treatment
failure

1.5
1
0.5
0

0

24

48

72

96

120 144
Time (h)

168

192

216

240

Fig. 3. Full simulated time–concentration curves for plasma and PELF.
Curve comparisons are by treatment outcome, and error bars represent
standard error. Statistical comparison yielded no significant differences
between outcomes in maximum concentration (plasma P = 0.12, PELF
P = 0.22).

weight was not a significant covariate in the nonlinear mixed
effects model.
The simulated full time–concentration curves for the treatment successes and failures can be found in Fig. 3. The Cl, V,
rate constants, CMAX, AUC0–t, AUC24, AUC0–∞, and MRT calculated from these curves were compared between treatment
successes and treatment failures, and no statistical differences
were observed. CMAX was, however, numerically higher in the
treatment success group. Variability was high, and this may or
may not be a true difference (plasma P = 0.12, PELF
P = 0.22).

MIC and pharmacodynamics
The MIC distribution for the clinical (BAL and NPS) isolates of
M. haemolytica (n = 287) and P. multocida (n = 257) from this
trial can be seen in Fig. 4. Isolates of M. haemolytica in the susceptible category represent 60% of the isolate population, and
those in the resistant category encompass 36% as compared to
31% and 68% for P. multocida, respectively. The isolates tested
were collected over all time points (0, 12, 24, and 120 h
post-treatment) from both CON and MM cattle and therefore
represent isolates not yet exposed to therapeutic drug as well as
isolates exposed to gamithromycin in the later sample collections. Additionally, nine of the 26 cattle diagnosed with BRD
and subsequently sampled were from the treatment group
receiving mass medication with gamithromycin on arrival and
would have therefore had previous exposure to gamithromycin.
The bivariate histogram in Fig. 5 shows the MIC distribution
for both M. haemolytica and P. multocida at time 0 by treatment outcome. This graphic suggests that the sample size was
not equivalent across outcome groups, but the MIC comparisons within outcome group are quite similar. As such, there
were just 22 cattle in the success group and 4 in the failure
group with the plots representing a single isolate per calf for
those yielding an isolate (4 calves did not yield an isolate at
time 0). Due to small sample size and confounding of arrival
treatment (CON and MM) within therapeutic treatment
outcome, it was not possible to statistically compare the MIC
by outcome. However, it can be visually appreciated that there
is a symmetry in each group with the treatment success group
having 10 susceptible isolates and 8 resistant isolates. The
treatment failures represent cattle yielding 2 susceptible and 2
resistant isolates, prior to treatment.
The results of the PK/PD index calculations can be found in
Table 5 and represent a comparison between treatment successes and failures by pathogen. Although the standard error
in the failure group is relatively large and likely reflective of
the small sample size, comparing the means between outcomes
indicate that in all cases, more active ingredient is present for
© 2015 John Wiley & Sons Ltd
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Fig. 5. Bivariate histogram of MIC distribution
of Mannheimia haemolytica and Pasteurella
multocida cultured from bronchoalveolar and
nasopharyngeal samples just prior to
treatment (time 0) for bovine respiratory
disease in 26 head of cattle (4 calves did not
yield an isolate at time 0).
Table 5. Pharmacokinetic/pharamcodynamic
indices for cattle treated with gamithromycin for
acute bovine respiratory disease [mean (SE)].
Parameter comparisons are by pathogen (cultured
at time 0) and treatment outcome within either
plasma or the effect compartment, PELF. Values
are calculated as free unbound drug using 26%
protein binding from a previous study (Huang
et al., 2010)

M. haemolytica
Parameter
Plasma

PELF

AUC24/MIC
AUC∞/MIC
CMAX/MIC
AUC24/MIC
AUC∞/MIC
CMAX/MIC
T>MIC

Success (SE)
1.32
3.49
0.09
31.5
205
1.86
77

‡

(0.1)
(0.4)‡
(0.01)‡
(4.4)
(29)
(0.26)
(10)

P. multocida

Failure (SE)
0.67
1.78
0.04
24.6
164
1.45
44

‡

(0.59)
(1.55)‡
(0.037)‡
(22.4)
(150)
(1.32)
(44)

Success (SE)

Failure (SE)

1.24
3.21
0.08
31.0
209
1.83
56

0.72
1.91
0.04
22.4
148
1.32
44

(0.41)
(1.07)
(0.03)
(9.8)*
(67)
(0.58)†
(19)

(0.42)
(1.12)
(0.03)
(11.7)*
(77)
(0.69)†
(25)

*P = 0.04; †P = 0.07; ‡P = 0.10.

a longer duration in the treatment success group. Statistical
differences between treatment successes and failures were
noted in AUC24/MIC (P = 0.04) for P. multocida in PELF. Additionally, an association (P = 0.10) was observed with higher
AUC24/MIC, AUC∞/MIC, and CMAX/MIC for treatment successes as compared to failures in plasma, and AUC24/MIC
(P = 0.07) in PELF for M. haemolytica. Half of the failures (2/4)
and 41% (7/17) of the cattle in the success group were from
the MM group that received gamithromycin on arrival to the
feedyard. Those cattle from the MM group accounted for 80%
(8/10) of the isolates displaying an MIC of ≥16 lg/mL (at time
0). The isolate yielding the highest MIC, as cultured prior to
treatment for BRD, is reported by treatment group (CON, MM)
in Table 6.
Comparison of the PK parameters resulting from this study
compared to those of previously published studies can be found
in Table 7. The calves in this study demonstrated an increased
Cl and V in plasma as compared to the healthy calves in the
two previous reports. The MRT of both plasma and PELF are
quite similar to those reported previously by Giguere et al. Both
the CMAX and AUC0–∞ reported herein are quite different, especially in plasma, from the previously published reports of gamithromycin PK in healthy cattle (Huang et al., 2010; Giguere
et al., 2011).

DISCUSSION
Trials involving sparsely sampled data, such as this one, represent difficulties in parameter estimation. Mixed effects models
© 2015 John Wiley & Sons Ltd

help to overcome these challenges by partitioning sources of
variability in hierarchical statistical models, thereby allowing a
reduction in the variance of the estimated population parameters. These models also have the advantage of allowing quality
analysis from fewer samples, thereby sparing expense and the
stress from additional animal handling. However, quality prior
information on the parameters is a requirement to inform these
models (Dodds et al., 2005; Riviere, 2011; Mould & Upton,
2012). It was fortunate to have had access to rich data to
externally validate the model. This allowed a comparison of
the simulated data in this study to the results of two previously
published reports to confirm the models’ accuracy.
Using only two samples of PELF per animal, the mixed
effect model utilized in this study allowed for the estimation
of the gamithromycin PK/PD values achieved in cattle diagnosed with BRD. The resulting simulated individual animal
profiles were used to run a NCA in order to compare our
model output to previous publication results. The PK parameter results obtained from that analysis are comparable to the
values obtained previously (Huang et al., 2010; Giguere et al.,
2011) as shown in Table 7. Considering the differences in
the physiological status of the study participants under investigation (healthy cattle in previous publications versus cattle
diagnosed with BRD in this report) and the fact that this
model under-predicts PELF, the resulting comparable PK
parameters from this study demonstrates that our two compartment plus PELF effect compartment model was acceptable.
However, the lower drug exposure found in the morbid
animals in this study as compared to those utilizing healthy
animals is noteworthy.
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Table 6. Minimum inhibitory concentration (lg/mL) comparison of
time 0 isolates from both PELF and NPS isolates by treatment group.
The single isolate with the highest MIC is reported for each calf (four
calves yielded no isolates at time 0)
ID

M. haemolytica

P. multocida

–
≥16.0
–
–
–
–
1.0
1.0
1.0
–
1.0
1.0
–
–
1.0
1.0
–

–
–
≥16.0
0.5
0.5
0.5
–
0.5
1.0
–
1.0
–
1.0
–
–
1.0
–

1.0
–
1.0
1.0
–
–
–
–

–
≥16.0
≥16.0
≥16.0
≥16.0
≥16.0
≥16.0
≥16.0

CON
102
104
106
116
118
126
174
175
222*
224
225
229
236*
240
241
243
245
MM
150
195*
204
206
209
212*
213
218
*Treatment failure.
– = culture yielded no isolate.

Table 4 displays the estimated typical values of the compartmental model parameters. It should be noted that the VPELF is
much larger than its actual physical volume in cattle because
the role of this parameter in the model is a virtual compartment in which relatively low concentrations were observed for
the administered dose.
Gamithromycin has been reported to be a low protein binding drug (26%) in the serum of healthy animals (Huang et al.,
2010). Protein binding was not an objective of this study and
therefore was not evaluated. Variation in protein binding is
expected to have minimal effect for drugs that display low pro-

No. animals
CMAX (lg/mL)
AUC0–∞ (lgh/mL)
Cl (mL/h/kg)
V (L/kg)
MRT (h)

Giguere et al.

Huang et al.
Plasma

Plasma

PELF

32
0.27
8.28
654*
56.9*
41.3*

30
0.43
7.95
830*
94.2*
43.1

30
4.61
348
–
–
71.1

tein binding. However, it is possible that alterations in the protein binding of the morbid animals in this study did have some
effect on the PK differences we observed. Future studies focusing on determining the differences between healthy and diseased animals needs to be considered to determine whether
this was simply an effect of the modeling/sampling strategy utilized in this study or a difference truly exists.
Much discussion is available in the literature surrounding
the selection of the proper pharmacodynamic index to determine the optimal dosing of the macrolide class of antimicrobials. Contemporary thought on the newer ‘longer acting’
injectable macrolides in veterinary medicine is that the most
important index is AUC/MIC. However, intense debate remains
whether this should be measured and reported for plasma
(Toutain, 2009; Papich, 2014), at the site of infection
(Amsden, 2001; Evans, 2005) or both (Rodvold et al., 2011).
Although not statistically significant, the marginally significant
association between plasma PKPD indices and treatment outcome (P = 0.10) would seem to substantiate the claims of
using plasma drug concentrations. However, we did observe a
significant association between PELF AUC24/MIC and treatment outcome (P = 0.04) with P. multocida, suggesting that
both plasma and PELF are correlated with treatment outcome.
This finding is not surprising given the fact that the drug in
the PELF is derived from and thus correlated with the drug in
the plasma. However, completely ignoring the PELF compartment and confining interpretation to plasma alone could be
misleading, especially when considering drugs with very extensive tissue distribution such as gamithromycin and other
macrolide class antibiotics.
Prior to the initiation of the study, gamithromycin did not
have clinical breakpoints determined by the CLSI. However,
since the conclusion of the live phase of this study, gamithromycin breakpoints have been reported for M. haemolytica,
P. multocida, and H. somni at ≤4.0, 8.0, and ≥16.0 lg/mL for
susceptible, intermediate, and resistant, respectively. The biphasic population of bacteria cultured from cattle displaying signs
of BRD in this report fit those breakpoints. Conversely, in this
study, there seemed to be little association between the
in vitro-determined MIC and treatment outcome, especially for
P. multocida (Table 7). Several authors have noted differences
between the MIC determined in vitro and the MIC determined
in the more physiologically relevant matrix, serum (Evans,
2005; Mitchell et al., 2012, 2013). It remains a possibility that

Current study
Plasma
26
0.13
5.4
1140
97.4
52.8

(0.003)
(0.13)
(27)
(2.4)
(0.18)

PELF
26
3.04 (0.09)
340 (12)
–
–
79.0 (0.29)

Table 7. Comparison of this study models simulated output of pharmacokinetic parameters to previously published work by noncompartmental
analysis. The label dose of 6 mg/kg subcutaneously was administered in each study. Values of
CMAX and AUC0–∞ are reported as total drug as
neither publication corrected for protein binding

SE where available; *Calculated from extrapolation of graphical data in manuscript.
© 2015 John Wiley & Sons Ltd
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the lack of association, in this study, between reported MIC
and treatment outcome could be due to a similar phenomenon.
Several cattle yielded multiple isolates of M. haemolytica and
P. multocida from either NPS or BAL, and selection of isolate
MIC was performed by choosing the isolate with the highest
MIC at time 0 (Table 6). Therefore, PD indices reported in this
study are likely to represent worst-case scenarios as the results
of this trial are also confounded by on arrival treatment
allocation. Giguere et al. reported MIC90 values of 0.5 and
1.0 lg/mL for M. haemolytica and P. multocida in 2011
(Giguere et al., 2011). Using those MICs would have certainly
resulted in much different PD indices.
Reported herein were the AUC/MIC ratios for both PELF and
plasma, as well as the other standard PKPD indices (CMAX/
MIC, T>MIC). Although minimal statistical differences were
observed, our findings indicate that for both M. haemolytica
and P. multocida, a longer drug exposure was more closely
related to a successful treatment outcome. While some small
differences in exposure were observed, it is unlikely that these
differences substantially contributed to the difference in clinical
outcome. However, it is important to keep in mind that due to
small sample size, there was a large amount of variability in
the data which could contribute to the lack of statistical significance.
Additionally, given the small numerical difference between
success and failure PD indices, it seems that there are likely
many factors beyond PK, PD, and MICs that contribute to the
success of a treatment regimen. For example, the immunological status of the animal and the environmental conditions that
the animal is subjected to undoubtedly also play a role in disease outcome. It has been shown that some macrolides have
anti-inflammatory and immunomodulatory effects in addition
to antimicrobial activity. Tulathromycin, a semi-synthetic
macrolide of the subclass triamilide, has been extensively
researched in this area (Fischer et al., 2011, 2013, 2014; Er &
Yazar, 2012; Duquette et al., 2015). Azithromycin, a macrolide of the same subclass as gamithromycin, has recently been
shown to exert anti-inflammatory properties on lung epithelial
cells in humans (Kitsiouli et al., 2015). While data specific to
gamithromycin are currently lacking in this area, it is possible
that anti-inflammatory activity similar to that of azithromycin
and tulathromycin could have facilitated a ‘self-cure’ in this
study. This should be further considered, especially considering
the high treatment success rate observed in this study given
the isolation of many resistant organisms as shown in Table 6.
There appears to be an over-representation of resistant
P. multocida isolates in the MM treatment group. This is likely
explained by the fact that gamithromycin was utilized for both
mass medication and treatment in this study, a practice that is
not common in the field. The reason for the lack of resistant
M. haemolytica in the MM group is not clear and deserves further attention in future studies.
Another layer of complexity must also be appreciated; there
remains a possibility that bacteria other than M. haemolytica
and P. multocida are responsible wholly, or in part, for the
treatment failures. While H. somni was isolated (data not
© 2015 John Wiley & Sons Ltd

shown), it was present very infrequently. It is possible that
another resistant pathogen is contributing to the clinical signs
associated with the BRD cases in this study.
This report is, to the authors’ knowledge, the first of its kind
in the veterinary literature, to perform such a large PK/PD
examining drug concentrations in PELF within a group of cattle experiencing naturally occurring BRD. Although challenged
by sample size limitations of ultimately diseased animals, a
compartmental PK model was developed to which the sparse
clinical data from this trial were successfully fit. Therefore,
complete concentration–time profiles were simulated for the
central and PELF effect compartment for each animal in order
to determine PK/PD indices for M. haemolytica and P. multocida
unique to each animal in this study. The findings from this
study indicate that PK variability in cattle diagnosed with BRD
seems at least as important as the MIC of M. haemolytica or
P. multocida. Additionally, further consideration should be paid
to other possible bacterial pathogens in association with BRD.
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